Climb Bio Stock Price Prediction
| CLYM Stock | 1.95 0.08 3.94% |
Oversold Vs Overbought
36
Oversold | Overbought |
Using Climb Bio hype-based prediction, you can estimate the value of Climb Bio from the perspective of Climb Bio response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Climb Bio to buy its stock at a price that has no basis in reality. In that case, they are not buying Climb because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Climb Bio after-hype prediction price | USD 2.43 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Climb |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Climb Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Climb Bio After-Hype Price Prediction Density Analysis
As far as predicting the price of Climb Bio at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Climb Bio or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Climb Bio, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Climb Bio Estimiated After-Hype Price Volatility
In the context of predicting Climb Bio's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Climb Bio's historical news coverage. Climb Bio's after-hype downside and upside margins for the prediction period are 0.12 and 7.39, respectively. We have considered Climb Bio's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Climb Bio is dangerous at this time. Analysis and calculation of next after-hype price of Climb Bio is based on 3 months time horizon.
Climb Bio Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Climb Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Climb Bio backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Climb Bio, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.98 | 4.96 | 0.26 | 0.16 | 5 Events / Month | 2 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.95 | 2.43 | 24.62 |
|
Climb Bio Hype Timeline
Climb Bio is currently traded for 1.95. The entity has historical hype elasticity of -0.26, and average elasticity to hype of competition of -0.16. Climb is anticipated to increase in value after the next headline, with the price projected to jump to 2.43 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 24.62%, whereas the daily expected return is currently at -1.98%. The volatility of related hype on Climb Bio is about 6149.27%, with the expected price after the next announcement by competition of 1.79. Climb Bio currently holds 2.87 M in liabilities. Note, when we think about Climb Bio's use of debt, we should always consider it together with its cash and equity.Given the investment horizon of 90 days the next anticipated press release will be in about 5 days. Check out Climb Bio Basic Forecasting Models to cross-verify your projections.Climb Bio Related Hype Analysis
Having access to credible news sources related to Climb Bio's direct competition is more important than ever and may enhance your ability to predict Climb Bio's future price movements. Getting to know how Climb Bio's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Climb Bio may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| DWTX | Dogwood Therapeutics, | (0.04) | 4 per month | 0.00 | (0.05) | 15.01 | (18.49) | 69.76 | |
| EPRX | Eupraxia Pharmaceuticals Common | 0.00 | 0 per month | 3.86 | 0.04 | 10.43 | (6.39) | 34.56 | |
| CEROW | CERo Therapeutics Holdings | 0.01 | 4 per month | 22.06 | 0.14 | 66.67 | (40.00) | 191.74 | |
| IRD | Opus Genetics, | (0.07) | 6 per month | 0.00 | (0.06) | 9.77 | (8.79) | 29.54 | |
| TLX | Telix Pharmaceuticals Limited | (0.30) | 8 per month | 1.72 | 0.07 | 4.38 | (3.18) | 10.19 |
Climb Bio Additional Predictive Modules
Most predictive techniques to examine Climb price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Climb using various technical indicators. When you analyze Climb charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Climb Bio Predictive Indicators
The successful prediction of Climb Bio stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Climb Bio, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Climb Bio based on analysis of Climb Bio hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Climb Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Climb Bio's related companies.
Story Coverage note for Climb Bio
The number of cover stories for Climb Bio depends on current market conditions and Climb Bio's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Climb Bio is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Climb Bio's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Climb Bio Short Properties
Climb Bio's future price predictability will typically decrease when Climb Bio's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Climb Bio often depends not only on the future outlook of the potential Climb Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Climb Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27.7 M | |
| Short Term Investments | 13.7 M |
Check out Climb Bio Basic Forecasting Models to cross-verify your projections. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.